research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
Search
for
Sort by
Research
210-240 / 1000+ results
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Jieduquyuziyin prescription alleviates SLE complicated by atherosclerosis via promoting cholesterol efflux and suppressing TLR9/MyD88 activation
Jieduquyuziyin prescription helps treat SLE with atherosclerosis by improving cholesterol removal and reducing inflammation.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
Tofacitinib may be safe and effective for treating certain skin conditions in children.
research Finasteride/flibanserin
research The use of oral pioglitazone in the treatment of lichen planopilaris
Pioglitazone may help treat lichen planopilaris, but more research is needed.
research Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases
Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
research Combination of Low-Dose Isotretinoin and Pulsed Oral Azithromycin in the Management of Moderate to Severe Acne
Low-dose isotretinoin combined with pulsed azithromycin cleared acne in most patients, with mild side effects.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
research Oral Tofacitinib for Refractory Lichen Planus Pigmentosus Coexisting with Frontal Fibrosing Alopecia
Tofacitinib significantly improved skin and hair conditions without side effects.
research Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
research Refractory cutaneous lichenoid sarcoidosis treated with tranilast
Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.